{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:36:54Z","timestamp":1781019414981,"version":"3.54.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that is widely used in B-cell lymphomas including follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Multiple clinical studies have shown that compared with rituximab combined with chemotherapy, obinutuzumab combined with chemotherapy can significantly improve the progression-free survival (PFS) of patients, effectively reduce the risk of disease progression, and improve patient prognosis. The main adverse effects of obinutuzumab include infusion reactions, myelosuppression, infection, cardiotoxicity, tumor lysis syndrome (TLS), etc., and in rare cases it may induce thrombocytopenia. However, so far there are few reports on \u201cobinutuzumab-induced acute thrombocytopenia\u201d (OIAT), especially severe cases. Here, we report a case of acute severe OIAT and review the literature to explore the management of this rare but life-threatening complication. The case is a 28-year-old young man who was diagnosed with stage IV follicular lymphoma and achieved remission after 8 cycles of R-CHOP chemotherapy. Later, he developed severe acute thrombocytopenia during maintenance treatment with obinutuzumab monotherapy, the patient\u2019s platelet count dropped from 191\u00d710^9\/L to 2\u00d710^9\/L on the 3rd day after the initial application, and severe thrombocytopenia occurred after multiple subsequent applications of obinutuzumab. OIAT is a rare but life-threatening complication. We should be aware of this adverse event and raise awareness about it.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1609862","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:28:10Z","timestamp":1755754090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Kun","family":"Kou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaolin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0112","article-title":"Obinutuzumab in the treatment of B-cell Malignancies: a comprehensive review","volume":"18","author":"Davies","year":"2022","journal-title":"Future Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","article-title":"Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis","volume":"11","author":"Luo","year":"2021","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014543271","article-title":"Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia","volume":"48","author":"Evans","year":"2014","journal-title":"Ann Pharmacother"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30781-7","article-title":"First-line obinutuzumab for follicular lymphoma","volume":"18","author":"Baker","year":"2017","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000381524","article-title":"Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin\u2019s lymphomas: a glycoengineered type II CD20 antibody","volume":"38","author":"Goede","year":"2015","journal-title":"Oncol Res Treat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.41","article-title":"Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab","volume":"30","author":"Freeman","year":"2016","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study","volume":"7","author":"Townsend","year":"2023","journal-title":"HemaSphere"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2828","article-title":"Obinutuzumab-related adverse events: A systematic review and meta-analysis","volume":"39","author":"Amitai","year":"2021","journal-title":"Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18826","article-title":"Obinutuzumab-induced acute thrombocytopenia: Report of two cases and review of literature","volume":"202","author":"Mechelfekh","year":"2023","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000751","article-title":"Successful use of intravenous immunoglobulins in an obinutuzumab-related acute thrombocytopenia","volume":"6","author":"Haage","year":"2022","journal-title":"Hemasphere"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19147","article-title":"Frequency and outcomes of obinutuzumab-induced thrombocytopenia","volume":"203","author":"Ng","year":"2023","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00838","article-title":"Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: A prospective analysis of the phase III GALLIUM study","volume":"42","author":"Pott","year":"2024","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0385","article-title":"Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101","volume":"10","author":"Dalle","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03360.x","article-title":"Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management","volume":"7","author":"Aster","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-07280-w","article-title":"Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies","volume":"49","author":"Kawasaki","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.42","article-title":"Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12","volume":"6","author":"Walter","year":"2016","journal-title":"Blood Cancer J"},{"key":"B20","article-title":"Acute thrombocytopenia after obinutuzumab administration in a patient with relapsed follicular lymphoma","volume":"61","author":"Sakai","year":"2020","journal-title":"Rinsho Ketsueki"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1609862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:28:11Z","timestamp":1755754091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1609862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1609862"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1609862","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"article-number":"1609862"}}